Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway

被引：1

作者：

Ravi, Gayathri ^{[1
]}

Giri, Smith ^{[2
]}

Bal, Susan ^{[3
]}

Godby, Kelly N. ^{[4
]}

Reddy, Vishnu V. B. ^{[5
]}

Salzman, Donna ^{[6
]}

Alkharabsheh, Omar ^{[7
]}

McDaniel, Scott A. ^{[8
]}

Sentell, Melissa ^{[6
]}

Costa, Luciano J. ^{[9
]}

机构：

[1] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA

[2] Univ Alabama Birmingham, Inst Canc Outcomes & Survivorship, Birmingham, AL USA

[3] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[4] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham Hosp, Birmingham, AL USA

[5] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA

[6] Univ Alabama Birmingham, Birmingham, AL USA

[7] Univ S Alabama, Mitchell Canc Inst, Mobile, AL USA

[8] Alabama Oncol Hematol Associates, Montgomery, AL USA

[9] Univ Alabama, Birmingham Hosp, Vestavia, AL USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-170099

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：8048 / 8049

页数：2

共 50 条

[21] Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Costa, Luciano J.
Chhabra, Saurabh
Medvedova, Eva
Dholaria, Bhagirathbhai R.
Schmidt, Timothy M.
Godby, Kelly N.
Silbermann, Rebecca
Dhaka, Binod
Bal, Susan
Gid, Smith
D'Souza, Anita
Hall, Aric
Hardwick, Pamela
Omel, James
Cornell, Robert F.
Had, Parameswaran
Callander, Natalie S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2901 - +
[22] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.
Rodriguez-Otero, Paula
Moreau, Philippe
Dimopoulos, Meletios Athanasios
Beksac, Meral
Perrot, Aurore
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
van de Donk, Niels W. C. J.
Schjesvold, Fredrik
Delforge, Michel
Einsele, Hermann
Spencer, Andrew
Lonergan, Sarah
Vieyra, Diego
Sitthi-Amorn, Anna
Carson, Robin L.
Blade, Joan
Boccadoro, Mario
Sonneveld, Pieter
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Kubicki, Tadeusz
Dytfeld, Dominik
Wrobel, Tomasz
Jamroziak, Krzysztof
Robak, Pawel
Czyz, Jaroslaw
Tyczynska, Agata
Druzd-Sitek, Agnieszka
Giannopoulos, Krzysztof
Nowicki, Adam
Szczepaniak, Tomasz
Lojko-Dankowska, Anna
Matuszak, Magdalena
Gil, Lidia
Pula, Bartosz Michal
Rybka, Justyna
Majcherek, Maciej
Usnarska-Zubkiewicz, Lidia
Szukalski, Lukasz
Konska, Agnieszka
Zaucha, Jan M.
Walewski, Jan
Mikulski, Damian
Czabak, Olga
Robak, Tadeusz
Kruk-Kwapisz, Dorota
Lahoud, Oscar Boutros
Zonder, Jeffrey A.
Griffith, Kent
Stefka, Andrew T.
Jiang, Ken
Cooperrider, Jennifer H.
Derman, Ben A.
Jakubowiak, Andrzej J.
BLOOD, 2023, 142
[24] Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2
Loiseau, Herve Avet
Sonneveld, Pieter
Moreau, Philippe
Offner, Fritz
van der Velden, Vincent H. J.
Caillot, Denis
Hulin, Cyrille
Arnulf, Bertrand
Corre, Jill
Mohty, Mohamad
Karlin, Lionel
Lambert, Jerome
Macro, Margaret
Perrot, Aurore
Levin, Mark-David
Klein, Saskia K.
Stoppa, Anne-Marie
Delforge, Michel
Zweegman, Sonja
Jie, Kon-Siong
Van De Donk, Niels W. C. J.
Krevvata, Maria
Rigat, Fabio
Yang, Shiyi
Vanquickelberghe, Veronique
de Boer, Carla
Kampfenkel, Tobias
Vermeulen, Jessica
Wuilleme, Soraya
Broyl, Annemiek
Bene, Marie C.
BLOOD, 2021, 138
[25] Sustained Minimal Residual Disease (MRD) Negativity and Clinical Efficacy in Transplant-Ineligible (TIE) Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Treated with Daratumumab-Based Regimens: Analysis of Maia and Alcyone
San-Miguel, Jesus F.
Avet-Loiseau, Herve
Paiva, Bruno
Kumar, Shaji K.
Dimopoulos, Meletios A.
Facon, Thierry
Mateos, Maria-Victoria
Touzeau, Cyrille
Jakubowiak, Andrzej
Usmani, Saad Z.
Cook, Gordon
Cavo, Michele
Quach, Hang
Ukropec, Jon
Ramaswami, Priya
Pei, Huiling
Sun, Steven
Wang, Jianping
Krevvata, Maria
DeAngelis, Nikki
Heuck, Christoph
Van Rampelbergh, Rian
Kudva, Anupa
Kobos, Rachel
Qi, Ming
Bahlis, Nizar J.
BLOOD, 2020, 136
[26] Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study
Sonneveld, Pieter
Moreau, Philippe
Dimopoulos, Meletios A.
Quach, Hang
Ho, P. Joy
Beksac, Meral
Hulin, Cyrille
Antonioli, Elisabetta
Leleu, Xavier
Mangiacavalli, Silvia
Perrot, Aurore
Cavo, Michele
Belotti, Angelo
Broijl, Annemiek
Gay, Francesca
Mina, Roberto
Nijhof, Inger S.
van de Donk, Niels W. C. J.
Katodritou, Eirini
Schjesvold, Fredrik
Sureda Balari, Anna
Rosinol, Laura
Delforge, Michel
Roeloffzen, Wilfried
Driessen, Christoph
Vangsted, Annette
Einsele, Hermann
Spencer, Andrew
Hajek, Roman
Jurczyszyn, Artur
Lonergan, Sarah
Liu, Yanfang
Wang, Jianping
Vieyra, Diego
van Brummelen, Emilie M. J.
Vanquickelberghe, Veronique
Sitthi-Amorn, Anna
de Boer, Carla J.
Carson, Robin
Blade, Joan
Boccadoro, Mario
Rodriguez-Otero, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S550 - S551
[27] Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD plus Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts
Paiva, Bruno
Manrique, Irene
Giuliani, Nicola
Cavo, Michele
Rojas, Christine
Fu, Weijun
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Vorog, Alexander
Li, Cong
Wang, Bingxia
Labotka, Richard J.
Dash, Ajeeta B.
BLOOD, 2020, 136
[28] Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes
Varga, Cindy
Robinson, Myra
Gupta, Vikas
Hofmeister, Craig C.
Nooka, Ajay K.
Kaufman, Jonathan L.
Dhodapkar, Madhav, V
Lonial, Sagar
Borden, Shanice
Ferreri, Christopher
Paul, Barry
Atrash, Shebli
Bhutani, Manisha
Voorhees, Peter M.
Joseph, Nisha S.
BLOOD, 2024, 144 : 4702 - 4703
[29] Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial
D'Agostino, Mattia
Oliva, Stefania
Rota-Scalabrini, Delia
Petrucci, Maria Teresa
Zambello, Renato
De Sabbata, Giovanni
Liberati, Anna Marina
Pietrantuono, Giuseppe
Tosi, Patrizia
Pisani, Francesco
Capra, Andrea
Velluti, Cristina
Galieni, Piero
Annibali, Ombretta
Monaco, Federico
Pascarella, Anna
Palmieri, Salvatore
Luppi, Mario
Cavo, Michele
Paris, Laura
Bruno, Benedetto
Musto, Pellegrino
Boccadoro, Mario
Gay, Francesca
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S6 - S7
[30] Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)
Popat, Rakesh
Cavenagh, James D.
Owen, Roger G.
Streetly, Matthew
Schey, Stephen A.
Koh, Mickey
Crowe, Josephine
Quinn, Michael F.
D'Sa, Shirley
Virchis, Andres
Cook, Gordon
Crawley, Charles
Pratt, Guy
Cook, Mark
Oakervee, Heather E.
Counsell, Nicholas
Adedayo, Toyin
Evans, Alison
Braganca, Nivette
Smith, Paul
Lyons-Lewis, Janet
Rabin, Neil
Yong, Kwee L.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →